Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
In Reply: In considering the impact of annual
dollar caps on drug benefits for Medicare beneficiaries, we characterized
15 of the top 20 medications driving their drug expenditures as for the treatment
of a "chronic" disease. This was to demonstrate that patients would likely
require continuing medical treatment even after exhausting their yearly drug
benefits. We took a conservative approach and included health conditions such
as cardiovascular disease, hypercholesterolemia, and diabetes.
Tseng C, Mangione CM. Cost-effectiveness of Treatment for Chronic Hepatitis C Infection—Reply. JAMA. 2003;290(15):1994–1995. doi:10.1001/jama.290.15.1994-a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: